captopril has been researched along with thromboplastin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camera, M; Di Santo, A; Lorenzet, R; Napoleone, E; Tremoli, E | 1 |
| Ishibashi, T; Maruyama, Y; Nagata, K; Nakazato, K; Ohkawara, H; Sakamoto, T; Seino, Y; Teramoto, T; Yokoyama, K | 1 |
| Blann, AD; Caine, GJ; Christodoulos, K; Harris, AL; Lip, GY | 1 |
| Chen, LF; Ke, YN; Li, N; Zhu, WL | 1 |
| Celi, A; Cianchetti, S; Del Fiorentino, A; Pedrinelli, R | 1 |
| Amore, C; Cugino, D; Cutrone, A; de Gaetano, G; Di Santo, A; Donati, MB; Iacoviello, L; Lorenzet, R; Napoleone, E | 1 |
6 other study(ies) available for captopril and thromboplastin
| Article | Year |
|---|---|
Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Blood Coagulation; Captopril; Cell Nucleus; Dimerization; Endotoxins; Gene Expression; Humans; In Vitro Techniques; Losartan; Monocytes; NF-kappa B; Proto-Oncogene Proteins c-rel; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Thromboplastin | 2000 |
Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Cells, Cultured; Culture Media; Humans; Monocytes; Peptidyl-Dipeptidase A; Plasminogen Activator Inhibitor 1; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Thromboplastin; Tumor Necrosis Factor-alpha | 2001 |
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; P-Selectin; Platelet Activation; Thromboplastin; Vascular Endothelial Growth Factor A | 2005 |
[Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor].
Topics: Animals; Captopril; Cells, Cultured; Endothelium, Vascular; Male; Proton-Translocating ATPases; Rabbits; RNA, Messenger; Tetrazoles; Thromboplastin; Valine; Valsartan | 2006 |
Aliskiren, a renin inhibitor, downregulates TNF-α-induced tissue factor expression in HUVECS.
Topics: Amides; Captopril; Down-Regulation; Endothelial Cells; Fumarates; Humans; Imidazoles; Renin; Tetrazoles; Thromboplastin; Tumor Necrosis Factor-alpha; Umbilical Veins | 2010 |
Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells.
Topics: Adenocarcinoma; Angiotensin-Converting Enzyme Inhibitors; Breast Neoplasms; Captopril; Cell Line, Tumor; Down-Regulation; Enalapril; Female; Humans; MCF-7 Cells; Neovascularization, Pathologic; Renin-Angiotensin System; Thromboplastin; Vascular Endothelial Growth Factor A | 2012 |